FDA Approves Bimekizumab for Moderate-To-Severe Plaque Psoriasis
Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.